A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements; Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma; LBCL With IRF4 Rearrangement; High-grade B-cell Lymphoma With 11q Aberration; Epstein-Barr Virus-Positive DLBCL; DLBCL Associated With Chronic Inflammation; Fibrin-associated LBCL; Primary Cutaneous DLBCL, Leg Type; Intravascular LBCL; Primary Mediastinal LBCL; High-grade B-cell Lymphoma; DLBCL Arising From Transformed Indolent Lymphoma; Mediastinal Gray Zone Lymphoma; FL Grade 3B; MCL

Interventions: Drug: ATA3219

Sponsors: Atara Biotherapeutics

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 14, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments